Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome )Clinical Mucopolysaccharidosis VI Clinical Trials Market | Page 5

Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global,
by End Point Status, 2016* 21
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global,
Average Enrollment Target Trends, 2011-2015 22
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Market, Global,
Clinical Trials by Sponsor Type, 2016* 23
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global,
Key Sponsors, 2016* 24
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global,
Top Companies by Phase, 2016* 25
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Global,
Ongoing Clinical Trials by Prominent Drugs, 2016* 26
View summary of this report @ http://www.radiantinsights.com/research/mucopolysaccharidosisvi-mps-vi-maroteaux-lamy-syndrome-global-clinical-trials-review-h1-2016
List of Figures
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials
by Region (%), 2016* 6
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials
and Average Enrollment by Top Countries, 2016* 7
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, Global, Clinical Trials
In Progress by Top Countries, 2016* 8
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, AsiaPacific, Top Countries (%), 2016* 9
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics Clinical Trials, Europe,
Top Five Countries (%), 2016* 10
Proportion of Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) to Metabolic
Disorders Clinical Trials, G7 Countries (%), 2016* 14
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, G7 Countries, Clinical
Trials by Phase, 2016* 15
Mucopolysaccharidosis VI (MPS VI) (Maroteaux-Lamy Syndrome ) Therapeutics, G7 Countries, Clinical
Trials by Trial Status, 2016* 16